title: Cost effectiveness of nonoperative management versus laparoscopic appendectomy for acute uncomplicated appendicitis.
abstract: BACKGROUND
  Appendectomy remains the gold standard in the treatment of acute, uncomplicated appendicitis in the United States. Nonetheless, there is growing evidence that nonoperative management is safe and efficacious.
  
  
  METHODS
  We constructed a decision tree to compare nonoperative management of appendicitis with laparoscopic appendectomy in otherwise healthy adults. Model variables were abstracted from a literature review, data from the Healthcare Cost and Utilization Project data, the Medicare Physician Fee schedule, and the American College of Surgeons Surgical Risk Calculator. Uncertainty surrounding parameters of the model was assessed via 1-way and probabilistic sensitivity analyses.
  
  
  RESULTS
  Operative management cost $12,213 per patient. Nonoperative management without interval appendectomy (IA) was the dominant strategy, costing $1,865 less and producing 0.03 more quality-adjusted life-years (QALYs). Nonoperative management with IA cost $4,271 more than operative management, but yielded only 0.01 additional QALY. One-way sensitivity analysis suggested operative management would become the preferred strategy if the recurrence rate was >40.5% or the total cost of appendectomy was decreased to <$5,468. Probabilistic sensitivity analysis confirmed nonoperative management without IA was the preferred strategy in 95.6% of cases.
  
  
  CONCLUSIONS
  Nonoperative management without IA is the least costly, most effective treatment for acute, uncomplicated appendicitis and warrants further evaluation in a disease thought to be definitively surgical.
authors.affiliation: Department of Surgery, UCLA David Geffen School of Medicine, Los Angeles, CA. Electronic address: JamesWu@mednet.ucla.edu.
authors.forename: James X
authors.initials: JX
authors.lastname: Wu
authors.affiliation: Department of Surgery, UCLA David Geffen School of Medicine, Los Angeles, CA; VA Greater Los Angeles Healthcare System, Los Angeles, CA; Department of Health Policy and Management, UCLA Fielding School of Public Health, Los Angeles, CA.
authors.forename: Aaron J
authors.initials: AJ
authors.lastname: Dawes
authors.affiliation: Department of Surgery, UCLA David Geffen School of Medicine, Los Angeles, CA; VA Greater Los Angeles Healthcare System, Los Angeles, CA; Department of Health Policy and Management, UCLA Fielding School of Public Health, Los Angeles, CA.
authors.forename: Greg D
authors.initials: GD
authors.lastname: Sacks
authors.affiliation: Department of Surgery, UCLA David Geffen School of Medicine, Los Angeles, CA.
authors.forename: F Charles
authors.initials: FC
authors.lastname: Brunicardi
authors.affiliation: Department of Health Policy and Management, UCLA Fielding School of Public Health, Los Angeles, CA; RAND Corporation, Santa Monica, CA.
authors.forename: Emmett B
authors.initials: EB
authors.lastname: Keeler
mesh_terms: D000208:Acute Disease; D000328:Adult; D000900:Anti-Bacterial Agents / Q000191:economics / Q000627:therapeutic use; D001062:Appendectomy / Q000191:economics* / Q000379:methods; D001064:Appendicitis / Q000191:economics / Q000601:surgery / Q000628:therapy*; D003131:Combined Modality Therapy / Q000191:economics; D003362:Cost-Benefit Analysis; D003663:Decision Trees; D004322:Drainage / Q000191:economics; D017048:Health Care Costs / Q000706:statistics & numerical data*; D006801:Humans; D010535:Laparoscopy / Q000191:economics*; D019057:Quality-Adjusted Life Years; D016896:Treatment Outcome; D014481:United States
chemical_list: D000900:Anti-Bacterial Agents